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Abstract: The 15q11.2 BP1-BP2 deletion (Burnside-Butler) syndrome is emerging as the most com-
mon cytogenetic finding in patients with neurodevelopmental or autism spectrum disorders (ASD)
presenting for microarray genetic testing. Clinical findings in Burnside-Butler syndrome include
developmental and motor delays, congenital abnormalities, learning and behavioral problems, and
abnormal brain findings. To better define symptom presentation, we performed comprehensive cog-
nitive and behavioral testing, collected medical and family histories, and conducted clinical genetic
evaluations. The 15q11.2 BP1-BP2 region includes the TUBGCP5, CYFIP1, NIPA1, and NIPA2 genes.
To determine if additional genomic variation outside of the 15q11.2 region influences expression of
symptoms in Burnside-Butler syndrome, whole-exome sequencing was performed on the parents and
affected children for the first time in five families with at least one parent and child with the 15q1l.2
BP1-BP2 deletion. In total, there were 453 genes with possibly damaging variants identified across all
of the affected children. Of these, 99 genes had exclusively de novo variants and 107 had variants
inherited exclusively from the parent without the deletion. There were three genes (APBB1, GOLGA2,
and MEOX1) with de novo variants that encode proteins evidenced to interact with CYFIP1. In
addition, one other gene of interest (FAT3) had variants inherited from the parent without the deletion
and encoded a protein interacting with CYFIP1. The affected individuals commonly displayed a
neurodevelopmental phenotype including ASD, speech delay, abnormal reflexes, and coordination
issues along with craniofacial findings and orthopedic-related connective tissue problems. Of the
453 genes with variants, 35 were associated with ASD. On average, each affected child had variants
in 6 distinct ASD-associated genes (x = 6.33, sd = 3.01). In addition, 32 genes with variants were
included on clinical testing panels from Clinical Laboratory Improvement Amendments (CLIA)
approved and accredited commercial laboratories reflecting other observed phenotypes. Notably, the
dataset analyzed in this study was small and reported results will require validation in larger samples
as well as functional follow-up. Regardless, we anticipate that results from our study will inform
future research into the genetic factors influencing diverse symptoms in patients with Burnside-Butler
syndrome, an emerging disorder with a neurodevelopmental behavioral phenotype.
Keywords: 15q11.2 BP1-BP2 deletion; Burnside-Butler syndrome; clinical findings; cognition;
neuropsychiatric behavior development; genomic characterization; exome sequencing; protein–
protein interaction
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1. Introduction
Chromosome 15 abnormalities have been reported for a number of years in the
medical literature, specifically for Prader-Willi (PWS) and Angelman (AS) syndromes, the
first examples of genomic imprinting in humans [1–4]. These disorders are generally due to
a chromosome 15q11-q13 deletion depending on the parent-of-origin (i.e., PWS—paternal,
AS—maternal). The typical 15q11-q13 deletions are classified as either Type I with deletions
involving the proximal 15q breakpoint (BP1) and a distal 15q breakpoint (BP3), or Type II
relating to a smaller 15q11-q13 deletion involving a second proximal breakpoint (BP2) and
distal BP3. The larger Type I deletion is approximately 6 Mb and includes the TUBGCP5,
CYFIP1, NIPA1, and NIPA2 genes, while the smaller Type II deletion is approximately
5.5 Mb with all four genes intact [5].
Clinical and behavior differences have been reported for the past 15 years involving
specific deletion classes in both PWS and AS. For example, individuals with PWS or
AS having the Type I deletion, generally have more learning and behavioral problems
compared to those with the Type II deletion [6,7]. Specifically, patients with PWS and larger
deletions have more compulsions and maladaptive behaviors, as well as lower cognition,
reading and math skills when compared to PWS patients with smaller deletions [3,5,6,8].
In AS, more impaired speech and seizure activity are noted in individuals with the larger
deletion [4].
The emerging 15q11.2 BP1-BP2 microdeletion (Burnside-Butler) syndrome (BBS) en-
compasses the region between the PWS/AS chromosome 15q deletion breakpoints and
includes the TUBGCP5, CYFIP1, NIPA1, and NIPA2 genes. This microdeletion was con-
sistently reported in early studies of patients presenting with unexplained behavioral,
cognitive, and/or psychiatric problems [9–11]. Ho et al. [12] later summarized the results
of ultra-high microarray single nucleotide polymorphism (SNP) analysis and found this mi-
crodeletion to be the most common cytogenetic finding observed in over 10,000 consecutive
patients studied and presenting for genetic services with features of ASD or other neurode-
velopmental disorders. Furthermore, a systematic literature review by Cox and Butler [10]
found over 200 individuals reported with this microdeletion and grouped the clinical find-
ings into five categories: (1) developmental, speech, and motor delays (73%, 67%, and 42%
of cases, respectively); (2) dysmorphic ears and palatal anomalies (46%); (3) writing and
reading impairment, memory problems, and verbal IQ scores ≤ 75 (50–60%); (4) general
behavior problems, unspecified (55%); and (5) abnormal brain imaging, including a smaller
brain surface with a thicker cortex (43%).
Notably, the four genes encoded in the 15q11.2 BP1-BP2 region are syntenic, bi-
allelically conserved, and functionally predicted to interact with each other along with
seven other genes (i.e., IGFBP2, CFHR1, CFHR3, MNS1, SPG20, BMPR2, and SPAST)
recently reported and analyzed via in silico studies and STRING functional interactions
network [13]. Rafi and Butler [13] also found that the encompassed four protein-coding
genes showed 11 nodes and 34 edges. Network nodes represent proteins with splice
isoforms or post-translational modifications collapsed into each node for all proteins
produced by a single protein-coding gene. Edges represent protein–protein associations
that jointly contribute to a shared function. These genes are at the center of our focus on
genomics and clinical findings in individuals with the 15q11.2 BP1-BP2 deletion.
A major focus of our report is to identify variants if present in the non-deleted alleles
of the four genes from the affected children in five unrelated families with the 15q11.2
BP1-BP2 microdeletion and characterize potential influences of genome-wide variation
on symptom expression using whole-exome sequencing in trios. We assessed clinical,
behavioral, and cognitive phenotypes as well as physical and motor development in
relationship to genetic findings in each subject in separate families, the first study of its
kind in this emerging syndrome.
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2. Results
Five families were studied. Each family included one parent and at least one child with
the 15q11.2 BP1-BP2 deletion, as confirmed by Methylation Specific-Multiplex Ligation
Probe Amplification (MS-MLPA) assays. Each family was initially ascertained via the child
having neurodevelopmental problems and/or ASD; chromosomal studies confirmed the
15q11.2 BP1-BP2 microdeletion. The parents were then cytogenetically analyzed to identify
the deletion and five families with six affected children (three males and three females)
were recruited for study.
2.1. Cognitive and Behavioral Features
Results of cognitive and behavioral testing obtained from members of five families
with the 15q11.2 BP1-BP2 deletion are shown in Tables 1 and 2. In terms of general
cognitive functioning, 9/11 individuals with 15q11.2 BP1-BP2 microdeletions performed in
the average to superior range; whereas, one affected child (Subject 3) scored just below the
normal range for full-scale IQ, and one affected child (Subject 11) was unable to complete
cognitive testing due to limited receptive and expressive language understanding and
severe developmental delay. Academic abilities (spelling, reading comprehension, and
math) were broadly commensurate with individuals’ cognitive abilities, though three
individuals showed spelling abilities at least 1 standard deviation (SD) below their verbal
abilities (Subjects 2, 3, and 9); one showed suppressed reading relative to verbal abilities
(Subject 3), and one showed suppressed math relative to their nonverbal abilities (Subject 7).
Verbal memory abilities appeared to be relatively intact among individuals. The majority
of participants performed within 1 SD of the mean across subscales of the California
Verbal Learning Test [14] (CVLT). Two participants (Subjects 1 and 3) scored below average
on most subscales, however, and Subject 10 performed 1.5 SD below the mean on long
delay recall and 3 SD below the mean on the recognition subscale. All individuals tested
performed within the normal range or above on the Peabody Picture Vocabulary Test,
Fourth Edition [15] (PPVT-4), indicating intact receptive language ability. Results from
the Trail Making tests [16] indicated performance in the average to superior range across
participants on Part A, demonstrating that psychomotor speed and planning was intact.
In contrast, 4/10 participants showed performance on Part B that was greater than one
1 SD below their performance on Part A, suggesting the ability to rapidly and flexibly shift
between response sets was selectively disrupted.
Results from Autism Diagnostic Observation Schedule, Second Edition [17,18] (ADOS-
2) testing suggested 3/6 affected children met testing criteria for a classification of ASD
(Subjects 2, 9, and 11; Subject 3 was 1 point below threshold). The Vineland Adaptive
Behavior Scale, Third Edition [19] (VABS-III) indicated that all of the children in our cohort
experienced deficits in a broad range of adaptive skills, with four of the six participants
scoring two standard deviations below the population average on at least one subscale. For
6/7 affected children, rates and severity of repetitive behavior were comparable to children
with ASD of similar ages [20]. The Broad Autism Phenotype Questionnaire [21] (BAP-Q)
indicated autism-associated traits in 2/5 affected parents (Subjects 1 and 6) based on score
thresholds defined by Sasson et al. [22]. Three of the five parents displayed repetitive
behavior severity that was comparable to individuals with ASD of similar ages [20].
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Table 1. Cognitive testing and results for families with 15q11.2 BP1-BP2 deletion.




































Perceptual 104 105 79 142 116 112 89 97 83 92 NT
Verbal 96 93 94 111 125 94 99 101 102 109 NT
Full Scale 100 99 84 128 124 103 93 99 92 101 NT
WRAT-IV
Reading 92 103 75 98 115 95 99 99 112 128 NT
Math 96 82 88 124 116 97 72 90 100 105 NT
Spelling 96 75 79 125 134 109 85 106 87 102 NT
CVLT-II/CVLT-C
Short Delay Free
Recall −1.5 0.5 −1.0 1.0 −0.5 0.5 0.0 1.0 −0.5 −0.5 NT
Short Delay Cued
Recall −1.5 0.5 −1.5 1.0 0.5 1.0 −1.0 0.5 −1.5 −0.5 NT
Long Delay Free Recall −1.5 0.0 −2.5 1.0 0.5 1.0 −1.0 0.0 −0.5 −1.5 NT
Long Delay Cued
Recall −1.5 0.5 −2.5 1.0 0.5 0.5 −0.5 0.0 −1.0 −0.5 NT
Recognition −2.5 0.5 0.5 0.0 −0.5 0.0 1.5 0.0 1.0 −3 NT
PPVT-4
Total Score 99 119 120 107 130 106 107 97 104 104 NT
Trail Making Test
Part A 130 129 92 126 99 110 88 111 107 119 NT
Part B 126 117 104 75 82 106 71 103 95 104 NT
Age in years (yr) and subject number for family members with the 15q11.2 BP1-BP2 deletion are indicated. NT: Not tested due to non-compliance. Scores for the CVLT are reported as z-scores (mean = 0,
std = ±1), scores for all other measures are normed scores with mean = 100, std = ±15.
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Table 2. Behavioral testing and results for families with 15q11.2 BP1-BP2 deletion syndrome.





































RRB NT 1 3 NT 0 NT 0 NT 4 NT 3 *
Social Affect NT 11 3 NT 3 NT 4 NT 5 NT 19 *
Total (ASD Cutoff = 7) NT 12 6 NT 3 NT 4 NT 9 NT 22 *
Classification NT Autism Non-Autism NT Non-Autism NT Non-Autism NT Autism NT Autism
BAP-Q
Total Score
(cut-offs: M = 3.55, F = 3.17) 5.33 NT NT 1.11 NT 3.67 NT 0.89 NT 3.28 NT
VABS-III (Standard
Scores)
Communication NT 54 77 NT 97 NT 70 NT 69 NT 36
Daily Living NT 60 82 NT 98 NT 92 NT 105 NT 46
Socialization NT 40 82 NT 82 NT 80 NT 80 NT 51
Adaptive Behavior
Composite NT 55 78 NT 90 NT 59 NT 82 NT 48
RBS-R
Overall Score 10 39 9 2 18 9 21 3 15 8 31
Age in years (yr) and subject number for family members with the 15q11.2 BP1-BP2 deletion are indicated. RRB: Restricted and repetitive behaviors, NT: not tested—measure was only administered to either
parent or child cohort. * These results are from ADOS-2 Module 1 rather than Module 3.
Int. J. Mol. Sci. 2021, 22, 1660 6 of 24
2.2. Sensorimotor Ability
Group means, standard deviations, and effect sizes for postural control are reported
in Table 3. Six children with the 15q11.2 BP1-BP2 deletion, six age- and sex-matched
control children, five affected parents, and four age- and sex-matched control adults
completed sensorimotor testing. Children with the 15q11.2 BP1-BP2 showed medium to
large elevations in center of pressure (COP) length (d = −0.64) and variability in medial-
lateral (ML) sway relative to control children (d = −0.70), and small increases in variability
of anterior-posterior (AP) sway (d = −0.38). Affected parents showed large increases in
COP length relative to control adults (d = −0.94), and these differences were medium for
variability of AP sway (d = −0.61).





BBS (n = 6) Control (n = 6) BBS (n = 5) Control (n = 4)
Mean (SD) Mean (SD) Cohen’s d Mean (SD) Mean (SD) Cohen’s d
COP Length (cm) 35.74 (21.37) 23.81 (15.36) −0.641 19.45 (11.15) 11.95 (1.36) −0.944
ML SD (log) −0.49 (0.34) −0.75 (0.40) −0.702 −1.02 (0.31) −1.06 (0.13) −0.166
AP SD (log) −0.32 (0.31) −0.42 (0.15) −0.383 −0.41 (0.32) −0.57 (0.19) −0.606
Group means and standard deviations (SD) for children and parents with the 15q11.2 BP1-BP2 deletion (BBS) and their matched controls as
well as effect sizes (Cohen’s d) for group comparisons. Negative effect sizes indicate greater variability for BBS children or adults relative to
controls. COP: center of pressure, ML SD: medial-lateral standard deviation, AP SD: anterior-posterior standard deviation.
2.3. Whole-Exome Sequencing
The per sequence Phred quality scale was above 35 for all the samples and 99.5%
of sequenced reads mapped to the genome, resulting in ~37.1 million mapped reads per
sample. There were 67,994 variants identified across the dataset. Of these, 526 were iden-
tified as high confidence, potentially damaging variants (PDVs) located in 453 distinct
genes in affected children (see Figure 1). Each affected child had an average of 100 PDVs
(x = 100.33, sd = 15.97) affecting 88 different genes (x = 88.00, sd = 12.88). The most preva-
lent type of PDV were missense variants (36.009%), followed by frameshifts (15.83%),
inframe insertions and deletions (InDels; 15.67%), splice site variants (9.17%), losses or
gains of stop codons (10.84%), protein altering variants (0.67%), and losses of start codons
(0.33%; Figure 2). Almost all types of variants had a proportion that were inherited, de
novo, or of unknown inheritance (Figure 2). In total, 132 of PDVs identified in affected
children were predicted de novo. Some variants that were de novo in one child were
observed inherited in others. Notably, there were 99 distinct genes with PDVs that were
exclusively de novo. In addition, there were 125 PDVs in 107 genes that were inherited
exclusively from the parent without the deletion.
There were three genes with PDVs that were exclusively de novo evidenced to encode
proteins that interact with the protein encoded by CYFIP1 which is located in the region
deleted in patients with BBS (Figure 3). These included an inframe deletion in APBB1 in
Subject 3, a missense mutation in GOLGA2 in Subject 2, and a missense mutation in MEOX1
in Subject 7. In particular, APBB1 is associated with ASD (Supplemental Table S1). As
noted above, Subject 3 was near the threshold for an ASD diagnosis based on the ADOS-2,
and had a history of global developmental delay (Table 4). Notably, the location of the
deletion identified in APBB1 affects a region of the protein that contains simple sequence
repeats (e.g., low-complexity region). As such, it is unclear whether or not this type of
variation would influence phenotype expression.
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Figure 1. Quality control and variant selection. Overview of the criteria used to select high confidence, potentially damaging variants from whole-exome sequence 
data. Maximum allele frequencies (Max AF) were based on the maximum observed frequency across all reference populations available in the 1000 Genomes Project, 
the European Standard Population, and the Genome Aggregation Database. Abbreviations: GQ = genotype quality, SNVs=single nucleotide variant, InDels = inser-
tion/deletion variant, DP = depth, VEP = Variant Effect Predictor. 
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sense mutations were identified in two genes. These included FAT3 where a PDV was 
observed in Subject 2; Subject 3 had the same variant in this gene and a variant in GOLGA2. 
Neither of these genes are associated with ASD or included on any of the evaluated clini-
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Figure 3. Genes with de novo variants with evidence for downstream relationships with CYFIP1. Shown are three genes 
prioritized following Ingenuity Pathway Analysis of all genes with de novo variants in affected children that were evi-
denced to be involved in the etiology of diseases relevant to symptoms observed in affected children. Included are protein–
protein interactions (PP) and diseases and functions where variation in the gene is causal (C). 
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in affected children that were inherited from parents without the 15q11.2 BP1-BP2 microdeletion that were also evidenced 
to be involved in the etiology of diseases relevant to symptoms observed in affected children. Included are protein–protein 
interactions (PP) and diseases and functions where variation in the gene is causal (C) or correlated (CO). 
Other genes of interest with PDVs were identified based on associations with clinical 
and physical findings in affected subjects as described in Tables 1, 2, 4, and 5. Notably, an 
average of 17 genes (𝑥 = 17.3, sd = 5.3) with PDVs in each patient were associated with 
ASD. As seen in Figure 5, Subject 2 had the most ASD-associated genes with PDVs (n = 
25). Compared to other affected children, Subject 2 also had the most severe repetitive 
behaviors measured via the Repetitive Behavior Scale – Revised [23] (RBS-R) and the most 
severe ADOS-2 score (Table 2). In addition, all affected children had PDVs in multiple 
genes that were included on clinical testing panels for intellectual disability (𝑥 = 8.7, sd = 
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interactions (PP) and diseases and functions where variation in the gene is causal (C).
Int. J. Mol. Sci. 2021, 22, 1660 9 of 24
Table 4. Medical history of families with 15q11.2 BP1-BP2 deletion.
Medical
History























Prenatal Mother age 46 yr Pre-eclampsia Gestational diabetes
Birth C-section C-section C-section C-section
Birth weight 3.4 kg (30th%) 3.6 kg(50th%) 3.7 kg (55th%)
3.8 kg
(75th%)
Neuro-develop-mental Learning difficulties Autism spectrumdisorder
Global develop-mental
delay Dyslexia, regression Learning difficulties Regression at 12mo
Neuro-




ADHD, OCD, ODD Sleep disturbance















Motor Weak postural control,walked at 16 mo
Fine and gross motor
delay, walked at 25 mo Walked at 12 months
Crawled at 20 months,














Skin Easy bruising, delayedhealing
Eczema, delayed
healing
Endocrine Diabetes mellitus Post-partum thyroiditis Delayed bone age,delayed growth Gestational diabetes
Reproductive PCOS
Immunologic Thymic hyper-trophy Anaphy-laxis
Age in years (yr) and subject number for family members with the 15q11.2 BP1-BP2 deletion are indicated. PCOS—polycystic ovarian syndrome, ADHD—attention deficit hyperactivity disorder, OCD—obsessive
compulsive disorder, ODD—oppositional defiant disorder, GAD—generalized anxiety disorder.
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Figure 4. Genes with variants transmitted from non-deleted parents to affected children with evidence for downstream
relationships with CYFIP1. Shown are genes prioritized following Ingenuity Pathway Analysis of all genes with variants in
affected childre t at were inherited from pare ts without the 15q11.2 BP1-BP2 microdeletion that were also evidenced to
be involved in the etiology of diseases relevant to symptoms observed in affected children. Inclu ed are protein–protein
interactions (PP) and diseases and functions where variation in the gene is causal (C) or correlated (CO).
Other genes of interest with PDVs were identified based on associations with clinical
and physical findings in affected subjects as described in Tables 1, 2, 4 and 5. Notably, an
average of 17 genes (x = 17.3, sd = 5.3) with PDVs in each patient were associated with
ASD. As seen in Figure 5, Subject 2 had the most ASD-associated genes with PDVs (n = 25).
Compared to other affected children, Subject 2 also had the most severe repetitive behaviors
measured via the Repetitive Behavior Scale – Revised [23] (RBS-R) and the most severe
ADOS-2 score (Table 2). In addition, all affected children had PDVs in multiple genes
that were included on clinical testing panels for intellectual disability (x = 8.7, sd = 4.7),
ataxia (x = 6.8, sd = 2.9), epilepsy (x= 6.2, sd = 2.8), comprehensive cardiovascular defects
(x = 2.8, sd = 1.1), and neuronal migration disorders (x = 2.0, sd = 1.1). There were four
subjects with PDVs in genes included on the cerebral cortical malformations panel, almost
all of whom had some evidence of neurological issues (Tables 4 and 5). Additionally, of
note, both Subjects 7 and 11 had PDVs in genes included on the testing panel for cleft
palate—GLI2 and FOXE1, respectively— and had craniofacial malformations involving the
mouth (Table 5). In addition, Subject 5 inherited a stop-loss variant in a connective tissue
disorder gene, FLCN, from the parent with the deletion (Subject 4) both of whom had a
history of musculoskeletal findings (Table 4). More details for all genes with PDVs meeting
our inclusion criteria are provided in the Supplemental Table S1.
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Table 5. Specific clinical evaluation and physical exam findings of families with 15q11.2 BP1-BP2 deletion.
Physical Exam
































































































length 19.2 cm (97th%) 20.2 cm (97th%) 15.6 cm (97th%)
16.3 cm






















(75th%) 5.2 cm (25th%)
















(25th%) NA 5.7 cm (50th%)












(>95th%) 27.6 kg (>95th%)































































than right Mild left ptosis
Mild bilateral
ptosis (L > R)
Myopia, right
sided ptosis
















Broad hands Soft fleshy,broad hands
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Table 5. Cont.
Physical Exam



















































carinatum Large body size
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4.7), ataxia (𝑥 = 6.8, sd = 2.9), epilepsy (𝑥= 6.2, sd = 2.8), comprehensive cardiovascular 
defects (𝑥 = 2.8, sd = 1.1), and neuronal migration disorders (𝑥 = 2.0, sd = 1.1). There were 
four subjects with PDVs in genes included on the cerebral cortical malformations panel, 
almost all of whom had some evidence of neurological issues (Tables 4 and 5). Addition-
ally, of note, both Subjects 7 and 11 had PDVs in genes included on the testing panel for 
cleft palate—GLI2 and FOXE1, respectively— and had craniofacial malformations involv-
ing the mouth (Table 5). In addition, Subject 5 inherited a stop-loss variant in a connective 
tissue disorder gene, FLCN, from the parent with the deletion (Subject 4) both of whom 
had a history of musculoskeletal findings (Table 4). More details for all genes with PDVs 
meeting our inclusion criteria are provided in the Supplemental Table S1. 
 
Figure 5. Number of genes with possibly damaging variants (PDVs) in each affected child associated with disorders of 
interest. Shown are the total number of genes with PDVs on the y-axis, that are also evidenced to be involved in the 
conditions on the x-axis. For autism spectrum disorder (ASD), evidence was based on the Simons Foundation for Autism 
Research Institute gene list. For other conditions, evidence was based on inclusion on clinical testing panels from Clinical 
Laboratory Improvement Amendments (CLIA) approved and accredited commercial laboratories. 
Figure 5. Number of genes with possibly damaging variants (PDVs) in each affected child associated with disorders of
interest. Shown are the total number of genes with PDVs on the y-axis, that are also evidenced to be involved in the
conditions on the x-axis. For autism spectrum disorder (ASD), evidence was based on the Simons Foundation for Autism
Research Institute gene list. For other conditions, evidence was based on inclusion on clinical testing panels from Clinical
Laboratory Improvement Amendments (CLIA) approved and accredited commercial laboratories.
3. Discussion
This study is the first of its kind to characterize phenotypic, behavioral, and cognitive
measures combined with exome sequencing in families with the 15q11.2 BP1-BP2 deletion.
An initial goal was to determine if the sequences of one or more of the four genes in
the 15q11.2 BP1-BP2 region showed a variant inherited from the parent with the intact
(non-deleted) chromosome. When disturbed, the four genes in the 15q11.2 region are
associated with cognitive impairment, speech and/or motor delay, dyslexia, and psychi-
atric/behavioral problems (e.g., attention deficit hyperactivity disorder (ADHD), autism,
schizophrenia, or psychosis). The cardinal disease associations for the four contiguous
genes in the 15q11.2 BP1-BP2 region are: NIPA1—Spastic Paraplegia 6; NIPA2—Angelman
syndrome and Prader-Willi syndrome; CYFIP1—fragile X syndrome and autism; and
TUBGCP5—Prader-Willi syndrome. The four genes are individually associated with PWS,
ASD, schizophrenia, epilepsy, and Down syndrome. Collectively, all four genes have
been associated with up to 75% of patients with ten distinctive neurodevelopmental
disorders [13].
The addition of newly reported findings including ataxia, poor coordination, seizures,
and congenital anomalies including palatal, heart, and ear defects along with structural
brain disturbances [11] which are also associated with the four genes in the 15q11.2 BP1-BP2
region raises the question of whether these genes interact with other genes, their biological
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processes or molecular functions. These related genes may play a role in the clinical
presentation causing core features of Prader-Willi and Angelman syndromes as additional
clinical structural differences are seen in those with the four genes deleted in the typical
15q11-q13 Type I deletion seen in these syndromes. For example, dysfunctional variation in
the NIPA1 and NIPA2 genes could impair the function of magnesium transport as both genes
encode magnesium transporters [24,25]. Their biological processes and molecular functions
could regulate axonogenesis and axon extension via relationships with bone morphogenetic
protein (BMP) and signaling pathways, regulations of cellular and developmental growth,
and interaction with the FMR1 gene causing fragile X syndrome [13]; all pertinent and
relevant to the reported variable clinical phenotypes seen in this microdeletion syndrome.
We used whole-exome sequence data to identify other genes outside of the deleted region
with possibly damaging variants to help detect genetic effects underlying expression of
symptoms in the affected child bringing the family to medical attention. Detailed physical
examinations and family pedigrees were performed, for the first time, by an experienced
clinical geneticist trained as a dysmorphologist to characterize the phenotype and review
of systems on each subject. In addition, cognitive and behavior testing, including motor
assessments for ataxia or balance disturbances of each family member, were performed
using various validated techniques and tests by experts in the field. These studies were the
major outcome measures for comparison with the genomic data and analysis for similarities
among our families with the 15q11.2 BP1-BP2 deletion.
3.1. Clinical and Neuropsychiatric Behavior Developmental Findings
We did not identify consistent patterns of cognitive impairments across individuals
with 15q11.2 BP1-BP2 microdeletion syndrome. General cognitive, academic, and receptive
vocabulary abilities were relatively intact with only one participant, Subject 11, not able
to complete standardized IQ testing, showing indications of intellectual/developmental
delay. Similarly, verbal memory abilities appeared to be unaffected across the majority
of participants, though 3/10 participants showed mild deficits in suggesting that more
selective issues in verbal memory and learning may impact a subset of individuals with the
15q11.2 BP1-BP2 microdeletion. Similarly, multiple participants (4/10) showed executive
deficits characterized by a reduced ability to flexibly shift response sets. These participants
were largely nonoverlapping with those showing verbal memory issues indicating that
these cognitive effects may be relatively distinct across individuals with 15q11.2 BP1-BP2
deletion syndrome. Several children had a history of learning problems reported by parents,
school records, or neuropsychological evaluations.
Our results suggest that individuals with 15q11.2 BP1-BP2 deletions have increased
risk for ASD. The prevalence of ASD in the general population is estimated to be 1 in 54
(1.8%) [26]; however, in our sample, we found that 3/6 (50%) of affected children met
testing standards for a diagnosis of ASD and 2/5 (40%) of affected parents demonstrated
elevated autistic traits (one additional child, Subject 3, and one additional parent, Subject 10,
scored just below the cutoff for the ADOS-2 and BAP-Q, respectively). Consistent with high
rates of ASD and ASD-related traits in our sample, we observed high rates of repetitive
behavior in a majority of our participants with 5/6 affected children and 3/5 adults
demonstrating severity of repetitive behavior that is comparable to similarly aged persons
with ASD [20]. Of note, our sample of 15q11.2 BP1-BP2 deletion carriers (parents) may
actually underrepresent the prevalence of ASD in the population of these carriers since
persons who are parents and those who volunteer to participate in research and travel
significant distances are likely to represent a cohort with relatively mild symptoms. Notably,
all of the affected children were observed to have variants in multiple genes that were
associated with ASD or found on the intellectual disability testing panel.
One limitation to classification of ASD in this sample is the use of only one observa-
tional diagnostic tool (the ADOS-2), rather than using a combination of clinical observation,
parent interviews and strict DSM-V criteria to confirm diagnosis; however, scores on the
ADOS-2 combined with scores on the Vineland and RBS-R strongly indicate elevated
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rates of ASD and ASD-related traits in our sample. Similar to findings from studies of
individuals with idiopathic ASD, the majority of our participants (9/11) showed adaptive
functioning abilities below the mean for their age. These findings suggest that the 15q11.2
BP1-BP2 deletion confers increased risk for ASD and functional impairments independent
of selective impacts on cognitive abilities.
Most of the individuals in this sample presented with at least one dysmorphic feature,
some of which were present across multiple families. Five had abnormal ear findings such
as broad, soft, fleshy, or overfolded ears. The child of Family C also had a smooth upper lip
and philtrum. In the case of Family E, both the father and child had a broad, round face as
well as broad hands. Flat feet were present in three individuals. Both the mother and child
of Family B had small upper incisors. Six of the participants had eye findings demonstrating
ptosis including both affected individuals from Family C and the father of Family E. The
connective tissue finding of mild scoliosis was observed in two unrelated individuals
whereas kyphosis was found in one other participant. Hyperextensibility or instability
of various joints was a common feature, with unrelated individuals demonstrating a
positive Beighton hyperflexibility score of at least six out of nine showing hypermobile
joints. The 6-year-old child of Family A had a history of ankle instability and wore leg
braces. Leg asymmetry was also found in two unrelated individuals. Pectus carinatum
was seen in one individual while four participants had loose, soft skin, and two unrelated
individuals had birth marks. Two unrelated affected children had a reported history of
delayed wound healing.
Neurological problems were also present in several children. Two were diagnosed
with epilepsy, one had non-essential tremor, and the child of Family D had gross hypotonia.
The mother and child of Family D were both found to have decreased deep tendon reflexes,
whereas the child of Family B had increased deep tendon reflexes. Ataxia was seen in the
child of Family E. Motor delay was also relatively common, with four affected children
showing delayed motor milestones. Motor deficits in affected individuals were also evident
in our tests of postural control. While this test does not have normed scores or clinical
cutoffs, group averages and effect sizes indicate that both children and adults with the
15q11.2 BP1-BP2 microdeletion show increased variability of postural sway relative to non-
affected controls. This is consistent with findings of increased variability of motor behavior
in neurodevelopmental disorders including Prader-Willi syndrome [27], ASD [28,29], and
fragile-X associated disorders [30], and involvement of ataxia-related genes in 15q11.2 BP1-
BP2. Of note, all affected children had PDVs in genes evidenced to cause ataxia, epilepsy,
comprehensive cardiovascular defects, and neuronal migration disorders. In addition,
many children had PDVs in genes involved in connective tissue disorders, cerebral cortical
malformations, micro/macrocephaly, and congenital malformations with craniofacial
defects that are included on the clinical cleft palate DNA testing panel.
3.2. Protein–Protein Interactions and Functions Related to NIPA1, NIPA2, CYFIP1 and
TUBGCP5 Genes in the 15q11.2 BP1-BP2 Region
Of particular interest are the genes that had either a de novo variant, or a variant
inherited from the parent without the deletion that encode proteins that interact with prod-
ucts of the four genes in the 15q11.2 BP1-BP2 region. As reported by Rafi and Butler [13]
when examining the protein–protein interactions of the four genes in the 15q11.2 BP1-BP2
region, the predicted biological processes can be summarized as follows: regulation of
cell growth, magnesium ion transmembrane transport, regulation of axonogenesis, regu-
lation of plasma membrane bounded cell projection organization, positive regulation of
axon extension, regulation of cellular response to growth factor stimulus, regulation of
developmental growth, positive regulation of cell projection organization, mitotic spindle
organization, regulation of BMP signaling pathway, and positive regulation of plasma
membrane bounded cell projection assembly.
Notably, NIPA1 protein was observed in our previous study to interact with 11 other
proteins. Five (45%) of the 11 proteins were members of the BMP superfamily, three (27%)
were BMP receptors and TGFB1 (9%) protein, indicating that three-fourths of the NIPA1
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interacting proteins are important for developmental bone morphogenesis or multifunc-
tional proteins that control proliferation, differentiation, and other functions in many cell
types. The NIPA2 protein interacted with 19 other proteins with three (16%) involved with
the BMP protein superfamily, three (16%) proteins interact with BMP receptors, ACVR1,
TGFBR1, and six members of the SMAD superfamily of proteins (42%); all playing a role as
intracellular signal transducers and transcriptional modulators activated by TGFB, thereby
impacting bone morphogenesis and its related functions. Specifically, the Spastin protein,
encoded by SPAST, was observed to interact with both NIPA1 and NIPA2. A variant in
SPAST was found in Subject 9. This child had hypotonia and history of fine and gross
motor delay as well as autism. Spastin severs polyglutamylated microtubules and likely
has a role in axon growth and branching [31,32]. Mutations in both SPAST and NIPA1
have been identified as causes of hereditary spastic paraplegia, a condition which causes
progressive weakness and spasticity of the legs [33,34]. De novo variants in SPAST are
evidenced to be associated with ASD with comorbid spastic paraplegia [35].
The CYFIP1 protein is also reported to interact with other proteins having a wide
range of activity with functions related to cytoskeleton organization and actin filament
binding with cell-matrix adhesion, MAP kinase signal transduction of cell growth, survival
and differentiation, stimulation of glucose uptake, intracellular protein breakdown and
tissue remodeling with mediation of translational repression [36]. We observed that five
additional genes with either a de novo or non-deleted parent inherited variant in the
affected child encode proteins that interact with CYFIP1. GOLGA2 encodes a protein that
acts as a membrane skeleton that maintains the structure of the Golgi apparatus. Mouse
models of this gene indicate its involvement in brain morphology and the development and
quantity of neurons [37,38]. Loss of this gene also resulted in ataxia in mice [37]. Subject 2
had a PDV in this gene as well as a disturbed motor phenotype, ASD, and neuropsychiatric
behavior developmental phenotypes. MEOX1 encodes a mesodermal transcription factor
that plays a key role in somitogenesis, specifically sclerotome development. MEOX1 is
involved in overall organism development in humans [39] and mutations in mice result
in evidence of congenital neurological disorders [40]. Subject 7 had a de novo PDV in
MEOX1 along with connective tissue defects, congenital malformations, epilepsy, and
neuropsychiatric behavior developmental phenotypes. Finally, FAT3 encodes an atypical
cadherin protein and may play a role in the interactions between neurites derived from
specific subsets of neurons during development. While FAT3 was not included in any
of the disease association categories we directly evaluated, missense mutations in this
gene are associated with the neurodevelopmental disorder, Hirschsprung disease (https:
//www.ncbi.nlm.nih.gov/clinvar/RCV000201304.1/) (accessed on 6 February 2021). Both
Subjects 2 and 3 had a PDV in this gene and evidence of a neurodevelopmental phenotype
and should be monitored for gastrointestinal issues.
3.3. Identified Gene Variants with Potential Clinical Significance
As the first effort to identify variants in the four 15q11.2 BP1- BP2 genes in this
microdeletion syndrome, we analyzed the non-deleted alleles in affected patients and
assessed family members as well, using whole-exome sequencing in order to compare
the genomic data of related genes with clinical, cognitive, and behavioral data. Some of
these variants are identified by the gene panels as potentially contributing to multiple
phenotypes in our subjects, as in the case of MLC1, which was a candidate for macrocephaly
and motor delay in Subject 9 and for contribution to epilepsy in Subject 7. All variants
passing inclusion criteria for possibly damaging the gene in which it is located, and the
corresponding evidence for clinical significance of having a variant in the gene, can be
found in Supplemental Table S1.
Other particular genes of interest with PDVs include numerous genes of the collagen
or COL group which code for proteins that make up various subtypes of collagen. Dis-
turbances in these genes are known to cause several connective tissue disorders [41]. For
example, in addition to the stop-loss variant in the connective tissue disorder gene FLCN,
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Subject 5—who had significant joint hyperextensibility—inherited a frameshift in COL5A3
from the parent with the deletion. Additional missense variants in collagen-encoding genes,
COL21A1 and COL6A2, were inherited from the non-deleted parent in Subject 7, who had
joint hyperflexibility. Specifically, variation in COL6A2 is associated with Ullrich congenital
muscular dystrophy 1 (https://omim.org/entry/254090) (accessed on 6 February 2021).
Subject 9 had an inframe deletion in COL4A3 and a missense variant in COL6A6 that was
inherited from the deleted parent. While no joint hyperflexibility was noted, this patient
had flat feet which may reflect collapse of connective tissues of the midfoot. Dysfunction
in collagen proteins may also manifest as other symptoms. COL4A3, for instance, is impli-
cated in disorders resulting in renal failure (https://omim.org/entry/120070) (accessed
on 6 February 2021) and Subject 9 was also noted to have a history of constipation. Fur-
thermore, variation in COL6A6 has been implicated in skin disorders [42]. Subject 11, also
without joint hyperflexibility, had the same missense variant identified in COL6A6 and had
birthmarks noted on the thigh and forehead.
Finally, CDK19 gene is another candidate explaining clinical findings in Subject 11 who
had a de novo missense variant in this gene. A disturbance in this gene has been associated
with bilateral congenital retinal folds, microcephaly, and intellectual disability [43]. Of
these findings, intellectual disability was present in Subject 11.
4. Materials and Methods
4.1. Families with 15q11.2 BP1-BP2 Deletion or Burnside-Butler Syndrome (BBS)
A total of five families with an affected child diagnosed with the 15q11.2 BP1-BP2 mi-
crodeletion were recruited and extensively evaluated using a series of cognitive, behavioral
and motor assessments, family and medical histories, physical examination, and exome
sequencing analyses. All participants or their legal guardians signed informed consent
forms approved by the Institutional Review Board at the University of Kansas Medical
Center (KUMC) before entry into the study. The five families included six affected children
(3 males and 3 females) with one family having two affected children (Family A, Subjects 2
and 3) with BBS. Four mothers and one father had a confirmed 15q 11.2 BP1-BP2 deletion.
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was
performed on two families for confirmation of the parents’ cytogenetic diagnoses using
existing methodology [36].
4.2. Cognitive and Behavioral Measures
Cognitive and behavioral assessments were administered to all members of our study
cohort (except where otherwise noted). All interviews and observational measures were
conducted by trained members of our study team. The following cognitive and behavioral
measures were administered:
The Wechsler Abbreviated Scales of Intelligence [44] (WASI-II) was used to assess
general cognitive abilities including verbal, perceptual (nonverbal), and full-scale IQ.
The Wide Range Achievement Test-4 [45] (WRAT-4) was used to assess basic academic
skills implicated previously in BBS, including sentence comprehension, word reading,
spelling, and math computation.
The California Verbal Learning Test [14] (CVLT) is a comprehensive assessment of
verbal learning and memory that specifically measures short delay free recall, short delay
cued recall, long delay free recall, long delay cued recall, and long delay recognition.
The CVLT-II was used in adolescents and adults (aged 16 to 89 years; N = 6), while the
California Verbal Learning Test for Children (CVLT-C) was administered to children (aged
5 to 16 years; N = 4).
The Peabody Picture Vocabulary Test, Fourth Edition [15] (PPVT-4) was used to assess
receptive vocabulary. During the PPVT-4, participants are instructed to identify the picture
that best matches a target word. The number of correctly identified pictures was examined.
The Trail Making Test [16] is a commonly used assessment of visual search, processing
speed, and cognitive flexibility consisting of two parts: Part A primarily measures visual
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search and processing speed as participants draw lines connecting numbers in sequential
order as fast as possible. Part B assesses cognitive flexibility as participants must alternate
between connecting letters and numbers as fast as possible (A-1-B-2-C-3, etc.). Reaction
time and the number of errors made were examined for Parts A and B.
The Autism Diagnostic Observation Schedule, Second Edition [17,18] (ADOS-2) is a
semi-structured play- and conversation-based assessment of the core social, communication,
and repetitive behaviors in ASD. Module 3 (for children/adolescents with fluent speech)
was used for all children in our study cohort except one non-verbal child, who as noted in
Table 2, was administered Module 1 (for children 31 months or older who are preverbal
or only use single words). The social-affective and total algorithm scores were examined.
Higher scores reflect more severe symptoms of ASD.
Broad Autism Phenotype Questionnaire [21] (BAP-Q) measures traits relating to
the broad autism phenotype—the presence of core diagnostic symptoms of ASD (e.g.,
social/communication impairments and restricted, repetitive behaviors) that occur below
the threshold for a clinical diagnosis. This questionnaire consists of three subscales: social
abnormalities, pragmatic language difficulties, and rigid personality and a desire for
sameness. The BAP-Q was administered only to the parents in our study cohort. We used
cutoff scores defined by Sasson et al. [22] (Males ≥ 3.55, Females ≥ 3.17), where higher
scores indicate greater presence of ASD traits.
Vineland Adaptive Behavior Scales-Third Edition [19] (VABS-III) is a series of semi-
structured caretaker interviews assessing current adaptive and daily living skills across
four domains: communication, daily living skills, socialization, and motor skills.
The Repetitive Behavior Scale—Revised [23] (RBS-R) is a rating scale that assesses
five categories of repetitive behavior (motor stereotypy, repetitive self-injury, compulsions,
routines/sameness, restricted interests) commonly observed in individuals with develop-
mental disabilities. Adult participants provided self-reported responses to the RBS-R, and
a parent or caregiver provided responses on behalf of the child participants. Higher scores
indicate greater severity of repetitive behavior. This measure does not have defined clinical
thresholds, so we compared scores to age-dependent averages from a large cohort study of
individuals with ASD [20].
4.3. Clinical Evaluation and Physical Examinations
A complete physical examination was performed by a clinical geneticist (MGB) with
anthropometric measures (e.g., head circumference, ear length, inner and outer canthal
distances, hand and mid-finger lengths) and data recorded including a three-generation
family pedigree. Past medical histories and review of systems were included for cognition,
behavior, seizures, pulmonary, cardiac, gastrointestinal, genitourinary, renal, musculoskele-
tal, cutaneous, immune, and hematology. Clinical photographs were obtained following
written consent.
4.4. Postural Control Testing
Participants completed a postural control task to assess gross sensorimotor ability.
Data for children and adult participants with the 15q11.2 BP1-BP2 deletion were compared
to age- and sex-matched control participants who were unrelated to the families affected
by the BBS deletion. Control participants completed postural control testing as part of
larger studies taking place at two separate research sites. Where noted, some of the task
parameters differed between these two sites.
Postural control was assessed using an AMTI (American Mechanical Technology, Inc.,
Watertown, MA, USA) AccuGait strain gauge force platform. Participants were tested bare
footed in a well-lit room. They were instructed to stand as still as possible on the platform
with their feet shoulder width apart and their arms resting at their sides. Participants
completed three trials each lasting 30–45 s.
To standardize the duration of data analyzed, the first five seconds of each trial were
removed and only the subsequent 20 s were included for analysis. Trials during which the
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participant lost balance or did not remain still for the duration of the trial (e.g., took a step,
sneezed, spoke, walked away, etc.) were excluded from analysis. Participants who had
fewer than two useable trials were excluded from analyses.
The center of pressure (COP) time series were derived from the force and moment
data during standing posture. The time series of each trial was down-sampled to 100 Hz
(for five control participants, data were down-sampled to 200 Hz) and low-pass filtered
using a fourth-order double pass Butterworth filter with a cutoff frequency of 6 Hz.
The variability of each participant’s postural sway was quantified using the standard
deviation (SD) of the COP in both the medial-lateral (ML) and anterior-posterior (AP)
directions, as has been done in previous studies [30]. SD values were log transformed to
correct for skewed distributions.
Data analyses were conducted separately for adults and children. Due to the small
sample size of this study, we limited our analyses to the calculation of group means,
standard deviations, and effect sizes (Cohen’s d) and interpreted as small (d = 0.2), medium
(d = 0.5), or large (d = 0.8) according to Cohen’s standards [46]. One child with the 15q11.2
BP1-BP2 deletion (Subject 11) did not complete any postural control testing, so data from
this participant and the matched control were not included in the analyses.
4.5. DNA Extraction
Saliva and buccal cells were collected using a Saliva DNA Collection and Preservation
Device (Norgen Biotek Corporation, Thorold, Ontario, CA, USA). Genomic DNA was iso-
lated and purified using a Saliva DNA Isolation Kit (Norgen Biotek Corporation) according
to manufacturer’s protocol.
4.6. Methylation Specific-Multiplex Ligation Probe Amplification (MS-MLPA)
The MS-MLPA assay is a standard laboratory assay to examine for chromosome
15 deletions and was used to identify the presence or absence of the 15q11.2 BP1-BP2
deletion prior to enrolling individuals in this study. MS-MLPA was performed using
reagents and kits obtained from MRC-Holland (Amsterdam, The Netherlands) including
ME028-C1 kits containing sequence specific probes along the length of the 15q11.2-q13
region. The C1 kit contains 47 MLPA probes for copy number detection using fragment
analysis following manufacturer’s instructions and reported elsewhere [36].
4.7. Whole-Exome Sequencing
Genomic DNA (5 µg) samples from four families (5 affected children and 4 sets of
parents) were exome sequenced at the KUMC Genomics Core facility, and one family
was sequenced in a commercial laboratory (GeneDx, Gaithersburg, MD, USA). Exome
sequencing was performed using the TruSeq Exome Library Prep Kit (Illumina FC-150-
1001, San Diego, CA, USA). High molecular weight (HMW) genomic DNA (gDNA) was
fragmented using the Covaris S2 Ultra-Sonication system. Following fragmentation, DNA
was end-repaired and 3’ adenylated prior to adaptor ligation using TruSeq DNA indexed
adapters. The DNA libraries were equalized to 233 or 250 ng and pooled for two rounds of
enrichment using the TruSeq Exome capture probes. TruSeq Exome capture probes target
45 Mb of coding sequence from >98% of RefSeq, Consensus CDS (CCDS), and Ensembl
coding content. Following the final exome capture, the enriched libraries were amplified
using polymerase chain reaction (PCR) to generate sufficient yield for sequencing. Enriched
amplified libraries were validated using the Agilent Bioanalyzer 2100 system and quan-
titated using the Roche LightCycler96 RealTime PCR system. Final library concentration
results were used to dilute the library pool to 2 nM and pooled for multiplexed sequencing
on a NovaSeq 6000 sequencing machine (Illumina, San Diego, CA, USA). The onboard
clonal clustering procedure was automated during the NovaSeq 6000 sequencing run.
The 100-cycle paired end sequencing was performed using the NovaSeq 6000 S2 Reagent
Kit—200 cycle (Illumina 20012861). Following sequencing, the raw base call files (.bcl)
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were converted to fastq files and de-multiplexed into individual libraries using Illumina’s
bcl2fastq2 software.
4.8. Variant Calling and Quality Control Procedures
The initial read quality was assessed using the FastQC software1 [47]. The sequenced
reads were then aligned to the human genome (hg38) using the Burrows–Wheeler aligner
(BWA) [48]. The initial read quality was assessed using the FastQC software1 [47]. The
sequenced reads were then aligned to the human genome (hg38) using the BWA [48].
Variant analyses of these data were performed in accordance with the Genome Analysis
Toolkit (GATK) variant calling best practices pipeline [49]. Variant calling was as follows:
The “MergeBamAlignment” tool was used to incorporate metadata to the aligned BAM
files. The “MarkDuplicates” tool was used to locate and tag duplicate reads in the BAM
files. The “BaseRecalibrator” tool was used to generate a recalibration table for base quality
score recalibration (BQSR). Known polymorphic sites obtained from the GATK resource
bundle were provided to this tool (Mills and 1000 G gold standard insertions or deletions
(InDels) hg38 vcf, Homo sapiens assembly38 dbsnp138 vcf). The “ApplyBQSR” tool was
run next in the two-stage process of base quality score recalibration. SNPs and InDels
were called using the “HaplotypeCaller” tool. The resulting gVCF files were combined
using the “CombineGVCFs” tool to form a multi-sample gVCF file. This file was passed
for Joint genotyping using the “GenotypeGVCFs” tool. A recalibration model to score
variant quality was built separately for InDels and SNPs using the “VariantRecalibrator”
tool. The tool “ApplyVQSR” was then used with these models in the second stage of
the variant quality score recalibration (VQSR) process to filter the input variants based
on the recalibration table. The resulting data were further processed using the Genotype
Refinement Workflow with the goal of improving the accuracy of genotype calls and
discarding unreliable genotype calls. The first step of this process was to calculate the
genotype posterior probabilities given family and known population genotypes using the
“CalculateGenotypePosteriors” tool. The pedigree information of the families and a high
confidence SNP file was provided to this tool. Variant calls were hard filtered to exclude
genotype quality scores less than 20 (GQ < 20.0).
Figure 1 shows additional quality control and variant selection details from the whole-
exome sequencing analysis. Specifically, single nucleotide variants (SNVs) were required to
have read depth ≥10, InDels were required to have depth ≥28X when 2–5 base pairs (bp)
long and ≥42X when 5–200 bps. To identify SNVs and InDels passing all quality control
that were potentially damaging, the functional effects of variants on encoded proteins were
predicted using the “SnpEff [50]” and Ensembl Variant Effect Predictor (VEP) tools [51].
Rare variants—with a maximum allele frequency (AF) <0.01% based on reference popula-
tions available in the 1000 Genomes Project, the European Standard Population and the
Genome Aggregation Database—located in protein coding gene transcripts were selected.
Rare variants predicted by VEP to have consequences that were moderately (i.e., inframe
InDels, missense, or protein altering) or highly likely (i.e., splice site alterations, gains or
losses of stop codons, loss of start codons, or frameshifts) to damage the protein products
were then prioritized. Missense and start loss SNVs were further evaluated for potential
deleterious effects using Sorting Intolerant From Tolerant (SIFT) [52], PolyPhen [53], and
Grantham substitution scores [54] with inclusion criteria as follows: SIFT score < 0.05,
PolyPhen score ≥ 0.70, and Grantham score ≥ 100 [54]. We then prioritized variants
in affected children that were predicted de novo, or inherited from only one parent as
additional evidence for potential clinical relevance.
4.9. Functional and Clinical Characterization of Genes with Variants
The implicated diseases and biological functions of the genes with variants of interest
were then identified using the Ingenuity Systems Pathway Analysis (IPA) tool [55]. Variant
effects analyses were run considering molecules and/or direct relationships that were
experimentally observed in mammals (i.e., humans, mice, rats) from all data sources. Two
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separate analyses were run on genes with de novo variants and genes with inherited
variants. As it was expected that de novo variants were more likely to represent clinically
relevant findings [56], variant effects analysis of genes with de novo PDVs were conducted
using evidence from all possible mutation consequences, including unclassified and silent
mutations. For genes with PDVs that were transmitted to affected children from the
parent without the 15q11.2 BP1-BP2 microdeletion, only evidence from likely damaging
mutation consequences (i.e., null, frameshift, loss of function, missense, gain-of-function,
knockout, in-frame, or nonsense mutations) were considered. In addition, as the specific
symptoms of affected children were diagnosed (see below for details on measures and
clinical evaluations), genes overrepresented at a Benjamini–Hochberg corrected p ≤ 0.05 in
diseases and disorders reflecting these symptoms were selected for follow-up. These genes
were then evaluated in Path Designer to determine if any direct or indirect relationships
were observed or predicted downstream of the four genes encoded in the 15q11.2 BP1-BP2
deletion region.
To further evaluate genes with PDVs that may relate to symptoms observed in
affected children, these genes were annotated based on evidence of associations with
ASD using the 2020 Q2 release of the Simons Foundation for Autism Research Initiative
(SFARI) gene list (https://gene.sfari.org/about-gene-scoring/) (accessed on 6 February
2021). In addition, genes were evaluated for inclusion on panels from Fulgent Genet-
ics (https://www.fulgentgenetics.com/) (accessed on 6 February 2021) and Prevention
Genetics (https://www.preventiongenetics.com/) (accessed on 6 February 2021), both Clin-
ical Laboratory Improvement Amendments (CLIA) approved and accredited commercial
laboratories. Interrogated panels from Fulgent Genetics included: epilepsy, intellectual dis-
ability, comprehensive cardiovascular defects, ataxia, microcephaly, macrocephaly, cerebral
cortical malformations, neuronal migration disorders and malformations including cleft
palate. Genes for connective tissue disorders reflected a combination of both the Fulgent
Genetics and Prevention Genetics panels as the latter panel was more comprehensive.
5. Conclusions
Our study of the 15q11.2 BP1-BP2 deletion (Burnside-Butler) syndrome, an emerg-
ing disorder, found variants in genes beyond the four genes in the chromosome 15q11.2
BP1-BP2 region using exome sequencing with our inclusion criteria and correlations with
reported gene and protein interactions with associated diseases or findings. Although
we cannot claim that the gene variants found are causal for the clinical, behavioral, or
cognitive findings observed (e.g., 9/11 subjects had adaptive functioning abilities below
mean for age; 8/11 subjects demonstrated repetitive behavioral scores comparable to ASD
subjects; 4 affected children tested had delayed motor milestones; joint instability or hyper-
extensibility was commonly observed) our data suggests that variants in genes encoded
outside of the 15q11.2 BP1-BP2 region may be of interest to future research. Notably, four
of the five probands in the five unrelated families inherited the 15q11.2 BP1-BP2 deletion
from the mother while only one father (Family E) had the deletion. The affected child in
Family E was also the most severely affected (ataxia, wheel-chair user, non-verbal, impaired
cognition). This may indicate parent of origin effects, similar to those reported in Davis
et al. [57], which included lower motor function and coordination when of paternal origin
and more cognitive and behavioral disturbances and seizures when of maternal origin. It
is also important to note that several families included in our study traveled long distances.
The travel and testing required for participation may have selected for affected children and
parents that are relatively less severe than others with this deletion. It is possible that many
less severe symptoms reported in this analysis dataset relate primarily to dysfunction in
the four core genes encoded in the 15q11.2 BP1-BP2 deleted region. Future studies focused
on ascertaining individuals with more severe expression of the symptoms we report may
identify more concrete evidence for damaging variants in other genes in addition to the
four core genes. Importantly, replication and functional studies are needed to confirm these
hypotheses. As noted in our study, a neurodevelopmental phenotype (autism, speech delay,
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abnormal reflexes, and coordination) was most commonly found along with craniofacial
findings (ear anomalies), and orthopedic or connective tissue problems (flat feet, scoliosis,
hypermobile joints). These clinical, cognitive, behavioral, and genomic characterizations
with reported protein interactions of the four genes of interest and associated diseases in
this chromosome 15q11.2 BP1-BP2 deletion did support a role in the neurodevelopmental-
autism phenotype seen in this emerging syndrome. Interaction with genes found and their
paralogs may have contributed, but our observations are preliminary on a small sample
size requiring replication. The authors hope that our findings will stimulate more research
and directions for study, shedding light on diagnosis, treatment, and prognosis for affected
individuals with this emerging syndrome having the most frequent microarray defect seen
in patients presenting with neurodevelopmental disorders.
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